血HLA-A、-B、-C、-DRB1、-DQB1 等位基因多态性与肝细胞癌发生关联研究*

doi:10.3969/j.issn.1672-5069.2018.06.028

Abstract

Abstract: Objective To analyze the correlation of HLA-A,-B,-C,-DRB1,-DQB1 allele polymorphisms to the development of hepatocellular carcinoma （HCC） in patients with hepatitis B. Methods 56 patients with HCC and underlying hepatitis B viral infection and 97 healthy persons were recruited in this study. Blood HLA-A,-B,-C,-DRB1,-DQB1 genes were detected by polymerase chain reaction sequence-based typing. Results The frequencies of HLA-A*02:03,A*02:07,HLA-B*46:01,HLA-DRB1*14:54,DRB1*12:02,HLA-DQB1*05:03 were significantly higher in patients with HCC than in the control,and they might be the risk factors for chronic hepatitis B patients developing HCC. While the frequencies of HLA-A*30:01 and HLA-B*13:02 were significantly lower in HCC group than in the control group. Conclusion In GuangDong province population,blood HLA-A*02:03,A*02:07,HLA-B*46:01,HL-DRB1*14:54,DRB1*12:02,HLA-DQB1*05:03 are positively correlated with the development of HCC.

Key words: Hepatocellular carcinoma, HLA, Alleles, Polymorphisms

Ouyang Shi, Chen Xiaoping, Cheng Tao, et al.. Correlation of HLA-A,-B,-C,-DRB1,-DQB1 alleles to hepatocellular carcinoma development in patients with hepatitis B viral infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 940-946.

References

[1] Maynard J E. Hepatitis B:global importance and need for control. Vaccine,1990,8 (Suppl 1):S18-S20,S21-S23.
[2] El-Chennawi FA,Auf FA,Metwally SS,et al.HLA-class II alleles in Egyptian patients with hepatocellular carcinoma. Immunol Invest,2008,37(7):661-674.
[3] Lavanchy D.Hepatitis B virus epidemiology,disease burden,treatment,and current and emerging prevention and control measures. J Viral Hepat,2004,11(2):97-107.
[4] Dragani TA.Risk of HCC:genetic heterogeneity and complex genetics. J Hepatol,2010,52(2):252-257.
[5] Baglioni S,Genuardi M.Simple and complex genetics of colorectal cancer susceptibility. Am J Med Genet C Semin Med Genet,2004,129C(1):35-43.
[6] Dibbens LM,Heron SE,Mulley JC.A polygenic heterogeneity model for common epilepsies with complex genetics. Genes Brain Behav,2007,6(7):593-597.
[7] Fukusato T,Gerber MA,Thung SN,et al.Expression of HLA class I antigens on hepatocytes in liver disease. Am J Pathol,1986,123(2):264-270.
[8] Moroso V,van Cranenbroek B,Mancham S,et al. Prominent HLA-G expression in iver disease but not after liver transplantation. Transplantation,2015,99(12):2514-2522.
[9] Strom SC,Gramignoli R.Human amnion epithelial cells expressing HLA-G as novel cell-based treatment for liver disease. Hum Immunol,2016,77(9):734-739.
[10] Singh R,Kaul R,Kaul A,et al.A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol,2007,13(12):1770-1787.
[11] Aptsiauri N,Cabrera T,Mendez R,et al.Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol,2007,601:123-131.
[12] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会. 原发性肝癌规范化诊断指南. 中华肝胆外科杂志,2015,21:145-151.
[13] Hacibektasoglu A,Barut A,Inal A.Relationship of histocompatibility groups to chronic HBV infections. Mikrobiyol Bul,1993,27(3):241-248.
[14] Maynard JE. Hepatitis B:global importance and need for control. Vaccine,1990,(Suppl8):S18-20,discussion S21-23.
[15] Mothe B,Llano A,Ibarrondo J,et al.Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med,2011,9:208.
[16] Begovich AB,Mcclure GR,Suraj VC,et al.Polymorphism,recombination,and linkage disequilibrium within the HLA class II region. J Immunol,1992,148(1):249-258.
[17] De Re V,Caggiari L,Simula M P,et al.Role of the HLA class II:HCV-related disorders. Ann N Y Acad Sci,2007,1107:308-318.
[18] Fallahi P,Ferri C,Ferrari S M,et al.Cytokines and HCV-related disorders. Clin Dev Immunol,2012,2012:468107.
[19] Longombardo G,Ferri C,Marchi S,et al.Immune response to an epitope of the NS4 protein of hepatitis C virus in HCV-related disorders. Clin Immunol Immunopathol,1998,87(2):124-129.
[20] Liu C,Cheng B.Association of polymorphisms of human leucocyte antigen-DQA1 and DQB1 alleles with chronic hepatitis B virus infection,liver cirrhosis and hepatocellular carcinoma in Chinese. Int J Immunogenet,2007,34(5):373-378.
[21] Donaldson PT,Ho S,Williams R,et al.HLA class II alleles in Chinese patients with hepatocellular carcinoma. Liver,2001,21(2):143-148.
[22] Xin YN,Lin ZH,Jiang XJ,et al.Specific HLA-DQB1 alleles associated with risk for development of hepatocellular carcinoma:a meta-analysis. World J Gastroenterol,2011,17(17):2248-2254.

Correlation of HLA-A,-B,-C,-DRB1,-DQB1 alleles to hepatocellular carcinoma development in patients with hepatitis B viral infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[2]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[3]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[4]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[5]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[6]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[7]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[8]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[9]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.
[10]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.
[11]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[12]	Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.
[13]	Fan Jiangao.. Highlights of Journal of Practical Hepatology in 2018 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 1-3.
[14]	Chen Yongqi, Chen Qian, Yuan Chunyan, et al.. Cancerous and noncancerous expression of Ep-CAM and C-Kit in patients with hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 109-112.
[15]	Yang Jing, Gao Lei.. Fitz-Hugh-Curtis syndrome:a case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 979-980.